Physician profile
Matt Mathew
NPI 1902804180
$4,885.43
in general payments reported to CMS, 2019-2025
21 companies · $875 in 2025
The $875 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $164 · 2021: $780 · 2022: $561 · 2023: $755 · 2024: $675 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.67 |
| Education | $103.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $881.15 | 2019-2023 | Korsuva, Veltassa |
| Amgen INC. | $781.20 | 2019-2024 | Parsabiv, Tavneos |
| Otsuka America Pharmaceutical, INC. | $653.09 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $463.40 | 2021-2025 | Terlivaz |
| Astrazeneca Pharmaceuticals LP | $440.42 | 2019-2023 | |
| Ardelyx, INC. | $437.75 | 2024-2025 | Xphozah 30 Mg |
| Travere Therapeutics, INC. | $228.01 | 2023-2025 | Filspari |
| Glaxosmithkline, LLC. | $164.16 | 2023 | Benlysta |
| Mallinckrodt Enterprises LLC | $137.93 | 2019 | |
| Ani Pharmaceuticals, INC. | $129.95 | 2023 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $106.61 | 2025 | Tarpeyo |
| Radius Health, INC. | $87.06 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.62 | 2022-2024 | |
| Fresenius USA Marketing, INC. | $61.75 | 2019-2024 | Korsuva, Velphoro |
| Novartis Pharmaceuticals Corporation | $56.90 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $50.29 | 2019 | |
| Nxstage Medical, INC. | $39.71 | 2019 | |
| Akebia Therapeutics INC | $24.95 | 2019-2020 | |
| Cormedix INC. | $19.81 | 2024 | Defencath |
| Aurinia Pharma U.S., INC. | $19.69 | 2022 | |
| Baxter Healthcare | $16.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matt Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.